Patents by Inventor Marc Allan Eichmeyer
Marc Allan Eichmeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10905756Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.Type: GrantFiled: June 22, 2018Date of Patent: February 2, 2021Inventors: Marc Allan Eichmeyer, Wesley Scott Johnson, Eric Martin Vaughn, Michelle L. Walz
-
Patent number: 10772950Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.Type: GrantFiled: June 22, 2018Date of Patent: September 15, 2020Inventors: Marc Allan Eichmeyer, Wesley Scott Johnson, Eric Martin Vaughn, Michelle L. Walz
-
Patent number: 10767213Abstract: The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.Type: GrantFiled: March 10, 2017Date of Patent: September 8, 2020Assignee: Boehringer Ingelheim Animal Health USA Inc.Inventors: Marc Allan Eichmeyer, Michael B. Roof, Merrill Lynn Schaeffer, Eric Martin Vaughn, Kun Yang, Jeremy Richard Rush, Daniel John Murfin
-
Patent number: 10624963Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.Type: GrantFiled: January 31, 2018Date of Patent: April 21, 2020Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
-
Patent number: 10576142Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: GrantFiled: February 1, 2018Date of Patent: March 3, 2020Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
-
Patent number: 10568955Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: April 19, 2018Date of Patent: February 25, 2020Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
-
Publication number: 20180289795Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.Type: ApplicationFiled: June 22, 2018Publication date: October 11, 2018Inventors: Marc Allan EICHMEYER, Wesley Scott JOHNSON, Eric Martin VAUGHN, Michelle L. WALZ
-
Publication number: 20180236057Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: April 19, 2018Publication date: August 23, 2018Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
-
Patent number: 10029005Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.Type: GrantFiled: February 23, 2016Date of Patent: July 24, 2018Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Marc Allan Eichmeyer, Wesley Scott Johnson, Eric Martin Vaughn, Michelle L. Walz
-
Publication number: 20180169214Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: ApplicationFiled: February 1, 2018Publication date: June 21, 2018Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
-
Publication number: 20180169213Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.Type: ApplicationFiled: January 31, 2018Publication date: June 21, 2018Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
-
Patent number: 9987349Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: March 21, 2016Date of Patent: June 5, 2018Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
-
Patent number: 9925255Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.Type: GrantFiled: June 30, 2015Date of Patent: March 27, 2018Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
-
Patent number: 9925256Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.Type: GrantFiled: June 30, 2015Date of Patent: March 27, 2018Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
-
Patent number: 9919041Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: GrantFiled: March 18, 2015Date of Patent: March 20, 2018Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
-
Publication number: 20170253908Abstract: The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.Type: ApplicationFiled: March 10, 2017Publication date: September 7, 2017Inventors: Marc Allan Eichmeyer, Michael B. Roof, Merrill Lynn Schaeffer, Eric Martin Vaughn, Kun Yang, Jeremy Richard Rush, Daniel John Murfin
-
Publication number: 20170232094Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.Type: ApplicationFiled: April 27, 2017Publication date: August 17, 2017Inventors: Gregory HAIWICK, Marc Allan EICHMEYER, Luis Alejandro HERNANDEZ, Wesley Scott JOHNSON, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN
-
Patent number: 9669087Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: March 18, 2015Date of Patent: June 6, 2017Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
-
Patent number: 9624527Abstract: The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyzes of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.Type: GrantFiled: February 28, 2014Date of Patent: April 18, 2017Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Marc Allan Eichmeyer, Michael B. Roof, Merrill Lynn Schaeffer, Eric Martin Vaughn, Kun Yang, Jeremy Richard Rush, Daniel John Murfin
-
Patent number: 9610345Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: GrantFiled: August 26, 2016Date of Patent: April 4, 2017Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer